U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H24ClNO.ClH
Molecular Weight 366.325
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPERASTINE HYDROCHLORIDE

SMILES

Cl.ClC1=CC=C(C=C1)C(OCCN2CCCCC2)C3=CC=CC=C3

InChI

InChIKey=UNPLRYRWJLTVAE-UHFFFAOYSA-N
InChI=1S/C20H24ClNO.ClH/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22;/h1,3-4,7-12,20H,2,5-6,13-16H2;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H24ClNO
Molecular Weight 329.864
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents.
2004
Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry.
2006
Effects of solid-state reaction between paracetamol and cloperastine hydrochloride on the pharmaceutical properties of their preparations.
2007 Apr 20
Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats.
2009 Nov
Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry.
2010 Feb 5
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats].
2010 May
Cloperastine-based cough syrup and acute dystonic reactions.
2012 Mar
Cloperastine rescues impairment of passive avoidance response in mice prenatally exposed to diethylstilbestrol.
2014 Feb
Patents

Patents

Sample Use Guides

10–20 mg three times daily for adults
Route of Administration: Oral
In Vitro Use Guide
Cloperastine inhibited the hERG K⁺ channels, expressed in HEK293 cells, in a concentration-dependent manner with an IC₅₀ value of 0.027 μM
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:35:28 GMT 2023
Edited
by admin
on Fri Dec 15 17:35:28 GMT 2023
Record UNII
PI4N7C63ND
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOPERASTINE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
1-(2-((P-CHLORO-.ALPHA.-PHENYLBENZYL)OXY)ETHYL)PIPERIDINE HYDROCHLORIDE
Common Name English
CLOPERASTINE HCL
Common Name English
CLOPERASTINE HYDROCHLORIDE [JAN]
Common Name English
Cloperastine hydrochloride [WHO-DD]
Common Name English
PIPERIDINE, 1-(2-((4-CHLOROPHENYL)PHENYLMETHOXY)ETHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
CLOPERASTINE HYDROCHLORIDE [MI]
Common Name English
CLOPERASTINE HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
239-067-8
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
CAS
14984-68-0
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
NCI_THESAURUS
C95235
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
EVMPD
SUB01367MIG
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
PUBCHEM
161104
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
FDA UNII
PI4N7C63ND
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
SMS_ID
100000087974
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID5045413
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
DAILYMED
PI4N7C63ND
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
MESH
C040282
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL415087
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
MERCK INDEX
m3654
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY Merck Index
RXCUI
2104181
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
DRUG BANK
DBSALT001087
Created by admin on Fri Dec 15 17:35:28 GMT 2023 , Edited by admin on Fri Dec 15 17:35:28 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY